Literature DB >> 7688057

Dimaprit, a histamine H2-agonist, inhibits anaphylactic histamine release from mast cells and the decreased release is restored by thioperamide (H3-antagonist), but not by cimetidine (H2-antagonist).

S Kohno1, K Ogawa, T Nabe, H Yamamura, K Ohata.   

Abstract

Whether anaphylactic histamine release from rat peritoneal mast cells is influenced by betahistine, a histamine H1-receptor agonist/H3-antagonist, and dimaprit, an H2-agonist, was examined. Treatment with dimaprit at 6 and 60 microM for 20 min significantly inhibited the anaphylactic histamine release, whereas betahistine at up to 80 microM under the same conditions did not affect it. Treatment with dimaprit at 6 and 60 microM for 1 to 20 min and for 5 to 20 min, respectively, caused a time-dependent inhibition of the release, but up to 30 min treatment with 8 and 80 microM betahistine had no effect. The decreased histamine release induced by dimaprit was recovered by neither mepyramine nor cimetidine. However, thioperamide, an H3-selective antagonist, dose-dependently restored the diminished release. From these results, the inhibition of anaphylactic histamine release by dimaprit is not produced by the stimulation of H2-receptors, but involves the stimulation of H3-like receptors or H3-subtype receptors, which are distinct from the H3-receptors located in brain, and suggests that the receptor plays an important role in the negative feedback regulation of histamine release.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7688057     DOI: 10.1254/jjp.62.75

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  2 in total

Review 1.  An update on histamine H3 receptors and gastrointestinal functions.

Authors:  G Bertaccini; G Coruzzi
Journal:  Dig Dis Sci       Date:  1995-09       Impact factor: 3.199

2.  Nitric oxide synthase inhibition by dimaprit and dimaprit analogues.

Authors:  J B Paquay; P A Hoen; H P Voss; A Bast; H Timmerman; G R Haenen
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.